CS Group (OTCQB: CSDX) Appoints Shah Teelani & Associates, a Dubai-Based PCAOB Auditor, to Consolidate All 2025 Financial Statements for CSDX, CS Interpharm GT LLC and CS Diagnostics Pharma GmbH

Core Insights - CS Diagnostics Corp. has appointed Shah Teelani & Associates, a PCAOB-registered audit firm, to consolidate and audit its 2025 financial statements, reflecting the company's commitment to financial governance and transparency as it expands internationally [1][2][4] Group Financial Reporting - The engagement with Shah Teelani & Associates aims to align the Group's financial reporting with U.S. public company standards and integrate its international operations under a unified reporting framework [2][4] - The consolidated audit will enhance financial clarity, streamline reporting processes, and strengthen investor confidence [2] Operational Focus - The 2025 consolidated financial review will include operations related to the MEDUSA hygiene and disinfectant platform and international distribution expansion [3] - The company is focused on expanding manufacturing partnerships, regulatory positioning, international distribution agreements, and capital markets readiness as part of its global growth strategy [4] Company Overview - CS Diagnostics Corp. is a medical technology company with a dual-focus platform in infection control and oncology, targeting high-priority global healthcare markets [5] - The company's portfolio includes the MEDUSA platform and CS Protect-Hydrogel, with ongoing commercialization milestones such as strategic partnerships and multi-region launches [5]